International non-profit coordinating large-scale cancer clinical trials, immunoprofiling research, and patient outcome standardization across 39 countries.
EORTC is a Brussels-based international non-profit that designs, conducts, and coordinates large-scale cancer clinical trials across Europe. They specialize in building multi-country patient cohorts, standardizing clinical data collection, and setting methodological standards for cancer treatment evaluation. Their work spans from early-phase biomarker validation to real-world evidence generation, serving as a neutral platform where academic hospitals, pharma companies, and regulatory bodies collaborate on improving cancer outcomes. They are particularly strong in immunoprofiling, patient-reported outcomes standardization, and big data integration for oncology.
IMMUcan (EUR 5.8M as coordinator) focuses on integrated immunoprofiling across colorectal, lung, breast, head & neck, and gastric cancers using deep cytometry, RNA-seq, and microbiome analysis.
MoTriColor, PIONEER, OPTIMA, and IMMUcan all involve multi-site cancer patient cohorts requiring standardized trial design and data harmonization across European centers.
SISAQOL-IMI (coordinator) sets international standards for analyzing patient-reported outcomes; HTx advances next-generation health technology assessment with real-world data synthesis.
IB4SD-TRISTAN (coordinator, 2017-2024) validates PET and MRI imaging biomarkers for drug safety assessment in lung, rheumatology, and toxicology contexts.
HARMONY builds a big data platform for leukemia, lymphoma, myelodysplastic syndromes, and multiple myeloma using real-life patient data.
EJP RD participation supports rare disease data sharing under FAIR principles, with emphasis on patient empowerment and public-private partnerships.
In the early period (2015–2018), EORTC focused on imaging biomarker validation (PET/MRI for drug safety), hematological malignancy data platforms, and molecularly guided treatment trials — work that was more diagnostic and data-infrastructure oriented. From 2019 onward, the focus shifted decisively toward cancer immunoprofiling (IMMUcan), real-world evidence and AI-driven treatment optimization (OPTIMA, HTx), and international standardization of patient-reported outcomes (SISAQOL-IMI). The trajectory shows a clear move from building data foundations to actively using those data for personalized, immune-focused cancer treatment decisions.
EORTC is moving toward AI-powered personalized oncology and immune-based treatment stratification, making them a strong partner for any consortium working at the intersection of cancer immunology and health data analytics.
EORTC operates as both a consortium leader and a trusted specialist partner, coordinating 3 of their 10 projects while contributing domain expertise to 7 others. With 361 unique consortium partners across 39 countries, they function as a major hub in European cancer research — their network reach is exceptional for an organization of this size. This breadth means partnering with EORTC gives access to a vast clinical trial network spanning most of Europe and beyond.
EORTC has collaborated with 361 unique partners across 39 countries, making them one of the most connected oncology organizations in H2020. Their network is truly pan-European with global reach, reflecting their role as a central coordinating body for international cancer trials.
EORTC occupies a rare position as a neutral, non-profit coordinating body for cancer clinical trials — they are neither a university, a hospital, nor a pharma company, which lets them serve as an honest broker across all three. Their combination of clinical trial methodology expertise, a massive established network of oncology centers, and increasing capability in immunoprofiling and real-world data analytics is hard to replicate. For any consortium needing credible, multi-country cancer patient access with standardized data collection, EORTC is often the first call.
